Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Zhang, Jing Ping ^a   Zhang, Hua ^a   Wang, Hong Bo ^a   Li, Yan Xian ^a   Liu, Gui Hong ^b   Xing, Shan ^a   Li, Man Zhi ^a   Zeng, Mu Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; Clonogenicity; Nasopharyngeal carcinoma; Sp1; Stem cell

Indexed keywords

BMI1 PROTEIN; CELL MARKER; KRUPPEL LIKE FACTOR 4; MITHRAMYCIN; MYC PROTEIN; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEM CELL; ANIMAL; CANCER STEM CELL; CELL ADHESION; CELL CLONE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DISEASE COURSE; EPITHELIUM CELL; METABOLISM; MIDDLE AGED; MOUSE; MULTICELLULAR SPHEROID; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; G1 PHASE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MALE; MICE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; S PHASE; SP1 TRANSCRIPTION FACTOR; SPHEROIDS, CELLULAR; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84905825297     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0222-1     Document Type: Article

References (48)

1. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007, 9:1-24. 17477889.
2. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5:423-428. 15144950.
3. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054. 15950718.
4. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P, Feng QS, Huang LX, Yu XJ, Li D, Chen LZ, Jia WH, Fang Y, Huang HM, Zhu JL, Liu XM, Zhao Y, Liu WQ, Deng MQ, Hu WH, Wu SX, Mo HY, Hong MF, King MC, Chen Z, Zeng YX. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002, 31:395-399. 12118254.
5. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative and temporal correlation between circulating cell-free epstein-barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:5452-5455. 10554016.
6. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. Serologic markers of epstein-barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001, 345:1877-1882. 11756578.
7. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma epstein-barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470. 15190138.
8. Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS, Jia WH. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst 2012, 104:1396-1410. 22972969.
9. Gallicchio L, Matanoski G, Tao XG, Chen L, Lam TK, Boyd K, Robinson KA, Balick L, Mickelson S, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: a systematic review. Int J Cancer 2006, 119:1125-1135. 16570274.
10. Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004, 22:3053-3060. 15284255.
11. Niu X, Hu C, Kong L. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2013, 139:1063-1071. 23525586.
12. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, Chan AT. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012, 23:1287-1292. 21948811.
13. Hirose T, Horvitz HR. An Sp1 transcription factor coordinates caspase-dependent and -independent apoptotic pathways. Nature 2013, 500:354-358. 23851392.
14. Karlseder J, Rotheneder H, Wintersberger E. Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol 1996, 16:1659-1667. 8657141.
15. Black AR, Jensen D, Lin SY, Azizkhan JC. Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 1999, 274:1207-1215. 9880488.
16. Khan S, Abdelrahim M, Samudio I, Safe S. Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 2003, 144:2325-2335. 12746293.
17. Duttenhoefer F, Biswas SK, Igwe JC, Sauerbier S, Bierhaus A. Sp1-dependent regulation of PPARalpha in bone metabolism. Int J Oral Maxillofac Implants 2014, 29:e107-e116. 24451878.
18. Chen Y, Huang Y, Huang Y, Xia X, Zhang J, Zhou Y, Tan Y, He S, Qiang F, Li A, Re OD, Li G, Zhou J. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer. Carcinogenesis 2014, 35:442-451. 24072772.
19. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004, 64:2030-2038. 15026340.
20. Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC, Hung JJ. Sp1 expression regulates lung tumor progression. Oncogene 2012, 31:3973-3988. 22158040.
21. Jungert K, Buck A, von Wichert G, Adler G, Konig A, Buchholz M, Gress TM, Ellenrieder V. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007, 67:1563-1570. 17308095.
22. Abdelrahim M, Samudio I, Smith R, Burghardt R, Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 2002, 277:28815-28822. 12052832.
23. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer 2002, 2:35. 12475396.
24. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:1648-1652. 18628415.
25. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003, 9:6371-6380. 14695137.
26. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010, 192:275-283. 20810260.
27. Majello B, De Luca P, Suske G, Lania L. Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins. Oncogene 1995, 10:1841-1848. 7753559.
28. Marampon F, Casimiro MC, Fu M, Powell MJ, Popov VM, Lindsay J, Zani BM, Ciccarelli C, Watanabe G, Lee RJ, Pestell RG. Nerve growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. Mol Biol Cell 2008, 19:2566-2578. 18367547.
29. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, Pages G, O'Rourke DM, Bernhard E, Maity A. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004, 15:4841-4853. 15342781.
30. Chen YJ, Chang WM, Liu YW, Lee CY, Jang YH, Kuo CD, Liao HF. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem Biol Interact 2009, 181:440-446. 19616522.
31. Chuang JY, Wu CH, Lai MD, Chang WC, Hung JJ. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer 2009, 125:2066-2076. 19588484.
32. Wang HB, Liu GH, Zhang H, Xing S, Hu LJ, Zhao WF, Xie B, Li MZ, Zeng BH, Li Y, Zeng MS. Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J 2013, 280:2929-2944. 23601184.
33. Zhao WF, Wang HB, Xie B, Hu LJ, Xu LH, Kuang BH, Li MZ, Zhang X. Sp1 and Sp3 are involved in the full transcriptional activity of centromere protein H in human nasopharyngeal carcinoma cells. FEBS J 2012, 279:2714-2726. 22682030.
34. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232. 16778197.
35. Willoughby JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009, 284:2203-2213. 19017637.
36. Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002, 21:1485-1492. 11896576.
37. Kavurma MM, Khachigian LM. Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem 2003, 278:32537-32543. 12796485.
38. Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010, 6:e1000940. 20532215.
39. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res 2007, 13:508-514. 17255272.
40. Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS. Prognostic relevance of centromere protein H expression in esophageal carcinoma. BMC Cancer 2008, 8:233. 18700042.
41. Liao WT, Feng Y, Li ML, Liu GL, Li MZ, Zeng MS, Song LB. Overexpression of centromere protein H is significantly associated with breast cancer progression and overall patient survival. Chin J Cancer 2011, 30:627-637. 21880184.
42. Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, Chen JB, Raif A, Jankowski K, Davies NP, Bekkum MV, Chen B, Tan O, Ellis T, Norris MD, Haber M, Kim ES, Shohet JM, Trahair TN, Liu T, Wainwright BJ, Ding HF, Marshall GM. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 2013, 32:3616-3626. 22907436.
43. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lemischka IR, Temple S. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell 2007, 1:87-99. 18371338.
44. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O, van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341. 17936558.
45. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, Le X, Suyun H, Huang S, Wang L, Xie K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011, 71:5182-5193. 21673052.
46. Kennedy BJ, Torkelson JL. Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 1995, 24:327-328. 7700186.
47. Stamp TC, Child JA, Walker PG. Treatment of osteolytic myelomatosis with mithramycin. Lancet 1975, 1:719-722. 47484.
48. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007, 110:2682-2690. 17973266.